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Abstract
Although myelin oligodendrocyte glycoprotein is a candidate
autoantigen in multiple sclerosis, its function remains
unknown. In humans, mRNA expressed by the myelin oligo-
dendrocyte glycoprotein gene is alternatively spliced resulting
in at least nine unique protein isoforms. In this study, we
investigated the sub-cellular localisation and membrane traf-
ﬁcking of six isoforms by cloning them into mammalian
expression vectors. Confocal microscopy revealed that these
protein products are expressed in different cellular compart-
ments. While two full-length isoforms (25.6 and 25.1) are
expressed at the cell surface, three alternatively spliced forms
(22.7, 21.0 and 20.5) have a more intracellular distribution,
localising to the endoplasmic reticulum and/or endosomes.
Isoform 16.3, which lacks a transmembrane domain, is
secreted. A switch in the sub-cellular localisation of myelin
oligodendrocyte glycoprotein may have profound effects on
receptor:ligand interactions and consequently the function of
the protein. The structural features of the alternative isoforms
and their differential, sub-cellular expression patterns could
dictate the exposure of major immunogenic determinants
within the central nervous system. Our ﬁndings highlight
myelin oligodendrocyte glycoprotein splicing as a factor that
could be critical to the phenotypic expression of multiple
sclerosis.
Keywords: alternative splicing, cellular trafﬁcking, human,
multiple sclerosis, myelin.
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Multiple sclerosis (MS) is a common, chronic disorder of the
central nervous system (CNS) often triggered in young
adults. Pathogenesis is characterised by inﬂammation,
destruction of the myelin sheath and axonal degeneration,
resulting in a disabling condition. MS is thought to be an
immune mediated disease (for review, see Sospedra and
Martin 2005). T-cell responses to many myelin proteins
including myelin basic protein, proteolipid protein, and
myelin oligodendrocyte glycoprotein (MOG) are observed in
MS patients and are thought to play a role in the pathogenesis
of the disease. Despite constituting only 0.05% of the total
myelin protein (Johns and Bernard 1999), MOG is a highly
signiﬁcant B cell autoantigen in MS, with antibodies against
MOG contributing to myelin destruction (Schluesener et al.
1987; Linington et al. 1988; Litzenburger et al. 1998; Storch
et al. 1998). Therefore, MOG is a unique antigen as it
triggers both inﬂammatory T-cell responses and demyelinat-
ing B-cell responses (Iglesias et al. 2001).
Despite the strong evidence of MOG as an autoantigen, its
precise function remains unknown (Johns and Bernard
1999). MOG is known to dimerise, however, its interactions
with other cellular proteins are undeﬁned. MOG is generally
thought of as a membrane-spanning glycoprotein found on
the outermost surface of the myelin sheath (Brunner et al.
1989; Scolding et al. 1989). It has an unusual protein
topology; after the extracellular IgV domain, MOG contains
a hydrophobic transmembrane (TM) domain, a cytoplasmic
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followed by a cytoplasmic tail (Kroepﬂ et al. 1996; della
Gaspera et al. 1998) (Fig. 1).
Myelin oligodendrocyte glycoprotein is encoded on chro-
mosome 6 in the major histocompatibility complex (Pham-
Dinh et al. 1993), a region of the genome encoding many
molecules important in the processing and presentation of
antigens to the immune system (Trowsdale 2001). The
mRNA product of the human MOG gene, but not the mouse
or rat analogues (Gardinier et al. 1992; Daubas et al. 1994),
can undergo signiﬁcant differential splicing, potentially
resulting in 17 protein isoforms (Hilton et al. 1995; Pham-
Dinh et al. 1995; Ballenthin and Gardinier 1996; Delarasse
et al. 2006). The MOG splice variants are capable of being
translated into functional proteins, hence, it is important to
consider the roles that individual isoforms play in the CNS,
and in MS. The expression of alternative MOG isoforms
could modulate protein interactions, the activity of the major
isoform, the sub-cellular localisation of MOG, and conse-
quently myelin maintenance.
The major splice forms investigated to date are shown in
Table 1. Alpha 1, the major variant investigated thus far, and
beta 1 are full-length isoforms, encoding proteins of 25.1 and
25.6 kDa, respectively. These two isoforms vary only in their
C-terminal amino acids encoded by exon 10; the C-terminal
amino acids encoded by the 10A exon are RNPF, while those
encoded by the 10B exon are LFHLEALSG (Fig. 1). Splice
forms alpha 4 and beta 4 utilise exon 3, an Alu-encoded
sequence that contains a stop codon. As none of the later
exons contribute to the protein produced, these two variants
result in the same truncated protein product, MOG 16.3 that
lacks a TM domain. This product is predicted to be secreted.
The other variants lack exon 8, which is believed to encode a
membrane associated region, and use alternative intron/exons
boundaries to produce a variety of alternative cytoplasmic
tails (Fig. 1). The resulting protein isoforms are predicted to
be 22.7, 22.2, 21.0, 20.5 and 20.2 kDa in size (see Table 1).
As the cytoplasmic tails of many transmembrane proteins
often contain motifs important in cellular transport, we
hypothesised that MOG variants with alternative cytoplasmic
(a)
(b)
(c)
Fig. 1 Composition of investigated myelin
oligodendrocyte glycoprotein (MOG) tran-
scripts and their products. (a) Exon struc-
ture of the six MOG transcripts of predicted
mRNA NM_002433 (25.6), NM_206809
(25.1), NM_206810 (21.0), NM_206811
(22.7), NM_206812 (20.5) and NM_206814
(16.3). (b) Alignment of amino acids enco-
ded by exons 3–10 of MOG transcripts. The
sequences were aligned using Clustal W
software. (c) Schematic representations of
the MOG isoforms (as suggested by Hilton
et al. 1995; Pham-Dinh et al. 1995; Ballen-
thin and Gardinier 1996). Protein molecular
weights are shown in kDa above each form.
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trafﬁcking of six of these isoforms; MOG 25.6, 25.1, 22.7,
21.0, 20.5 and 16.3 (Fig. 1). We report that variation in the
cytoplasmic tails of MOG isoforms has profound affects on
its cellular localisation and transport.
Materials and methods
Plasmids
The alpha 1 variant (MOG 25.1) was isolated from human brain
cDNA (Stratagene) by PCR ampliﬁcation using primers 5¢ CCT-
GAGATCTGGAACAGTAGAGATGGCAAGC 3¢ with a BglII site
and 5¢ GGACACCGTTGAAGGGATTTCGTAGC 3¢ containing an
AgeI site. This was subsequently cloned into pcDNA3.0 (Invitrogen
Life Technologies, Paisley, UK) containing a cytomegalovirus
promoter. We constructed MOG variants beta 1 (MOG 25.6), beta 3
(MOG 22.7), beta 5 (MOG 21.0), alpha 2 (MOG 20.5) and alpha 4/
beta 4 (MOG 16.3) from the alpha 1 variant plasmid by sequential
PCR ampliﬁcation using 5¢ tailed antisense primers. The PCR
primer sequences were as follows: MOG25.6-R 5¢CAGGACC-
GGTGCCAGAGAGGGCTTCCAGGTGGAAGAGTAGCTCTTC-
AAGGAATTGCCCTGCTAGTC3¢, MOG21.0-R 5¢CCACACCG-
GTGCCAGAGAGGGCTTCCAGGTGGAAGAGTAGCTCTTCA-
AGGAATTGCCC3¢, MOG22.7-R1 5¢CCACACCGGTCTTTTT-
TGGTTCCTTAACCTGGGGTCCTAGAACACCAAAGGACTC-
AAAAGTCCGGTGGAGATTCTC3¢, MOG22.7-R2 5¢CCACA-
CCGGTGCCAGAGAGGGCTTCCAGGTGGAAGAGTAGCTCT
TCAAGGAATTGCCCTGTCTTTTTTGGTTCCTTAAC3¢, MOG-
20.5-R 5¢GGACACCGGTGAAGGGATTTCGTAGCTCTTCAAG-
GAATTGCCCAAAAGTCCGGTGGAGATTCTC3¢, MOG16.3-R1
5¢CCACACCGGTGTGCCACTGCAACCAATCCTGGGTCACA-
GAGTGAGACACTTCTACTTTCAATTCCATTGCTG3¢, MOG-
16.3-R2 5¢CCACACCGGTCTTGAGCCTGGGAGGTGGAGGC-
TGCAATGAGCCATGATCGTGCCACTGCAACCAATCCTGG3¢.
All variants were cloned into pcDNA3.0 and were also cloned into a
mammalian cell vector (provided byAlison Gillingham, MRC-LMB,
Cambridge, UK) containing a C-terminal green ﬂuorescent protein
(GFP) tag. Sequence analysis using BigDye technology was
preformed to ensure all vectors were correct and in-frame.
Immunoﬂuorescence
ThehumanoligodendrocytecelllineMO3.13(McLaurin et al.1995)
(a kind gift from Neil Cashman, University of British Columbia,
Canada) and HeLa cells were grown on glass coverslips in
Dulbecco’s modiﬁed Eagle’s medium (Invitrogen Life Technologies)
supplemented with 10% heat-inactivated foetal calf serum, 20 mmol/
L HEPES, 2 mmol/L glutamine, 100 lg/mL streptomycin, and
100 U/mL penicillin. MO3.13 and HeLa cells were transiently
transfected using FuGene 6 transfection reagent (Roche, Lewes, UK)
or HeLa Monster (Mirus, Madison, WI, USA), respectively.
Approximately, 36 h post-transfection cells were stained for immu-
noﬂuorescence. MO3.13 cells were ﬁxed and permeabilised in
acetone. HeLa cells were ﬁxed in 4% paraformaldehyde and
permeabilised with 0.5% (v/v) Triton X-100 in phosphate-buffered
saline (PBS). After blocking in 20% (v/v) heat-inactivated foetal calf
serum, 0.5% (v/v) Tween 20 in PBS, cells were stained with primary
antibodies. To detect untagged MOG, cells were stained with the
MOG speciﬁc mAb 8.18C5 (a kind gift from Robert Harris,
Karolinska Institutet, Stockholm, Sweden). In addition, antibodies
speciﬁc for cellular compartments including the plasma membrane
(Rat anti-CD44, PharMingen, Oxford, UK), early endosomes (mouse
anti-EEA1, BD Transduction Laboratories, Oxford, UK), endosomes
(anti-Vps26, a kind gift from Matthew Seaman, University of
Cambridge, UK), the endoplasmic reticulum (ER) (rabbit anti-
calreticulin, Calbiochem, San Diego, CA, USA), lysosomes (mouse
anti-LAMP2, Developmental Studies hybridoma bank, University of
Iowa, IA, USA), and the cis-Golgi (mouse anti-GM130, BD
Transduction Laboratories) were also used. Staining with primary
antibodies was subsequently detected with species-speciﬁc Alexa
secondary antibodies (Molecular Probes, Paisley, UK). Cells were
mounted in ﬂuoromount-G (Southern Biotechnology Associates,
Birmingham, AL, USA) and images obtained using a Zeiss confocal
microscope (Carl Zeiss Microimaging GmbH, Hamburg, Germany).
To track MOG internalised into cells, antibody internalisation
experiments were performed. 36 h post-transfection cells were
continuously incubated with mAb 8.18C5 for 2 h at 37 C to allow
Table 1 MOG splice isoforms
Variant
Exon composition
Isoform name/
protein size 123 4567891 0
Alpha 1          A MOG 25.1
+
Alpha 2         A MOG 20.5
+
Alpha 3          A MOG 22.2
Alpha 4     *       A MOG 16.3
+
Beta 1          B MOG 25.6
+
Beta 2        B MOG 20.2
Beta 3          B MOG 22.7
+
Beta 4     *       B MOG 16.3
+
Beta 5         B MOG 21.0
+
*Exon 3 encodes a stop codon therefore the protein product is truncated and none of its later exons contribute to the amino acid sequence.
+Isoforms selected for further investigation in this study.
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internalised. The cells were washed of excess antibody, ﬁxed and
permeabilised as above, then stained with antibodies speciﬁc to the
endocytic/ lysosomal pathway. After washing, primary antibodies
were detected using species-speciﬁc Alexa secondary antibodies.
Radiolabelling
Around 36 h post-transfection, cells were harvested, washed in PBS
then starved for 1 h at 37 C in methionine/cysteine-free RPMI 1640
(Sigma, Poole, UK) supplemented with 2 mmol/L glutamine, 5%
dialysed foetal calf serum, and 10 mmol/L HEPES. Cells were
labelled with 1 mCi [
35S] methionine and [
35S] cysteine Pro-mix
(Amersham Pharmacia; GE Healthcare, Little Chalfont, UK)/10
7
cells for 10 min at 37 C. Cells were chased in culture medium
supplemented with excess unlabelled cysteine/methonine for
0–240 min, harvested, then washed in ice-cold PBS.
Immunoprecipitation
Radiolabelled cells were lysed in 1% Triton X-100 lysis buffer
[150 mmol/L NaCl, 20 mmol/L Tris, 1 mmol/L EDTA, 5 mmol/L
MgCl2 with 1 mmol/L phenylmethylsulfonyl ﬂuoride and protease
inhibitors (Roche)]. After centrifugation at 17 000 g for 10 min to
remove cell nuclei and debris, supernatants were pre-cleared on a
mixture of sepharose and protein A sepharose beads (Amersham
Biosciences) for 1 h at 4 C. To immunopreciptiate MOG isoforms,
2 · 10
6 cells were incubated with 2 lg 8.18C5 for 1 h on ice,
before incubation with protein A sepharose (Amersham Bioscienc-
es) for 1 h at 4 C. Unbound proteins were removed by washing the
beads three times in 0.5% Triton X-100 lysis buffer, before bound
proteins were eluted in sodium dodecyl sulphate sample buffer with
100 mmol/L beta-mercaptoethanol. Proteins were then digested with
1000 U of Endo Hf (New England Biolabs, Beverly, MA, USA) for
2 h in G5 buffer at 37 C to allow quantiﬁcation of the amount of
MOG exported through the secretory pathway to the medial Golgi.
Gel electrophoresis and immunoblotting
To detect any secreted MOG, GFP-transfected cell culture supern-
atants were collected, any cells were removed by centrifugation,
then the clariﬁed medium was mixed with sample buffer. Whole cell
lysates were made in sample buffer. Protein samples were separated
by sodium dodecyl sulphate-polyacrylamide gel electrophoresis. For
metabolically labelled proteins, gels were ﬁxed in 40% methanol,
12% acetic acid, and dried before images were obtained using a
phosphor screen (Perkin-Elmer, Waltham, MA, USA) and storm
scanner (Molecular Dynamics; Amersham Pharmacia) or on ﬁlm.
For immunoblotting, proteins were transferred to an Immobolin
membrane (Millipore) and blocked in 5% (w/v) dried milk, 0.05%
(v/v) Tween 20 in PBS. Membranes were incubated with a rabbit
polyclonal to GFP (Abcam, Cambridge, UK) followed by species-
speciﬁc horseradish peroxidase secondary Abs (DAKO, Ely,
UK), before detection by enhanced chemiluminescence reagent
(Amersham Biosciences).
Screening for MOG RNA expression
Brain samples from MS patients and controls were obtained by the
UK Multiple Sclerosis Tissue Bank, Imperial College London by
written consent and approved by Multicentre Research Ethics
Committee (MREC/02/2/39). The institute’s general safety commit-
tee and Peterborough and Fenland Local Research Ethics Committee
approved experimental procedures. RNA was extracted using TRI
REAGENT method (Sigma). In addition, brain RNA from control
samples from Stragene and Clonetech were included in this study.
RNA samples were DNase I treated prior to reverse transcription
using a DNA-free kit (Ambion, Huntingdon, UK). First strand
cDNA was synthesised from 4 lg of extracted RNA using
Transcriptor Reverse Transcriptase (Roche). The unique combina-
tions of exon–exon pairings within the splice variant cDNA
sequences were used to design speciﬁc PCR assays for the analysis
of their expression. The PCR primer sequences were as follows:
EX2–3 F 5¢GGAATTGAAAGTAGAAGTGTCTCAC3¢, EX2–4 F
5¢GCAATGGAATTGAAAGTAGAAGAT3¢, EX6–9 F 5¢CGGAC
TTTTGGGCAATTC3¢, EX6–10BR 5¢TTCCAGGTGGAAGACA
AAAG3¢, EX7–9R 5¢CTTCAAGGAATTGCCCTGTC3¢, EX8–9R
5¢CTTCAAGGAATTGCCCTGCT3¢, EX9–10BR 5¢GGCTTCC
AGGTGGAAGAGTA3¢, EX10A-10BR 5¢TTCCAGGTGGAA
GACTGGAG3¢. The primer pair combinations for each splice
variant-speciﬁc PCR (svPCR) assay were: MOG 25.1/MOG 25.6
(full-length variants; alpha/beta 1) EX2–4 F with EX8–9R, MOG
20.5 (alpha 2) EX6–9 F with EX10A-10BR, MOG 20.2 (beta 2)
EX2–4 F with EX6–10BR, MOG 22.2/MOG 22.7 (alpha/beta 3)
EX2–4 F with EX7–9R, MOG 16.3 (alpha 4) EX2–3 F with
EX10A-10BR, MOG 16.3 (beta 4) EX2–3 F with EX9–10BR.
An assay was not achieved for MOG 21.0 (beta 5). Ampliﬁ-
cation was performed in a volume of 20 lL containing 200 lmol/L
dNTP, 500 nmol/L primer, 2.5 mmol/L MgCl2, 10 mmol/L Tris–
HCl (pH 8.3), 50 mmol/L KCl, 0.3U AmpliTaq Gold poly-
merase (Applied Biosystems, Foster City, CA, USA), and 1 lLo f
the cDNA reaction. Cycling was performed as follows: 12 min at
95 C; cycles of 95 C for 25 s, 58 Co r6 2  C for 45 s, 72 C for 30 s,
and a ﬁnal extension step of 30 s at 72 C. PCR products were
electrophoresed in 1% or 3% agarose gels containing ethidium
bromide, and predicted size products were visualized under UV
light.
Expected products sizes for Alpha/Beta 1, Alpha 2, Alpha/Beta 3,
Alpha 4, Beta 2, Beta 4 were 310, 305, 245, 718, 196, 487 bp,
respectively. The PCR products were sequenced to conﬁrm their
identity. Plasmid controls were also used to verify PCR speciﬁcities.
A PCR for glyceraldehyde-3-phosphate dehydrogenase was used as
a control for cDNA synthesis.
Results
Isoforms of MOG exhibit different rates of export from
the endoplasmic reticulum
To determine if variation in the cytoplasmic tails of MOG
isoforms affects trafﬁcking, we initially investigated the rate
of export of MOG. To this end, the different MOG isoforms
were cloned into expression vectors and transiently ex-
pressed in HeLa cells. After metabolic labelling of MOG
transfected HeLa cells, samples were chased for 0–240 min,
and then the MOG isoforms were immunoprecipitated with
the MOG-speciﬁc mAb 8.18C5. The samples were subse-
quently treated with Endo H, an enzyme that does not cleave
processed N-linked sugars, a modiﬁcation indicative of
transit to the medial Golgi. This revealed that export of
1856 L. H. Boyle et al.
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similar, with each protein gaining 50% Endo H resistance
in 4 h (Fig. 2a). In contrast, isoform 21.0 remained totally
Endo H sensitive (Fig. 2a), suggesting that the majority of
MOG 21.0 protein was retained in the ER. Similar results
were obtained with MOG 20.5, with the majority of the
protein remaining Endo H sensitive after 4 h (Fig. 2a). The
three exported forms, 25.6, 25.1 and 22.7 contain a potential
membrane-associated region in their cytoplasmic tails,
speciﬁcally sharing a motif VLGP·V. In contrast, the two
isoforms that exhibited slower export, 21.0 and 20.5, lack
this region/motif. These results suggest that the cytoplasmic
tail encoding the VLGP·V motif is essential for the export of
MOG isoforms from the ER.
MOG isoform 16.3 is secreted
MOG 16.3 is predicted to be secreted as it lacks the TM
domain. The pulse/chase analysis suggested that MOG 16.3
was indeed secreted from transfected HeLa cells since the
protein disappeared over the chase time to very low levels
after 4 h (Fig. 2a). The secretion of MOG 16.3 was conﬁrmed
by the detection of GFP tagged MOG 16.3, but not the other
isoforms, from culture supernatant of transfected HeLa cells
by western blotting (Fig. 2b). Interestingly, a novel band of
30 kDa was associated with the MOG 16.3 isoform at the
30 minchaseperiod.Thisbandmayrepresentaproteinligand
that uniquely associates with MOG 16.3 (Fig. 2a). We are
currently attempting to identify this molecule.
MOG 25.6 and 25.1 are expressed on the cell surface
Next, we investigated the speciﬁc cellular distribution of
MOG isoforms containing the TM domain via confocal
microscopy using the MOG-speciﬁc mAb 8.18C5. As
expected, the major isoform of MOG previously investi-
gated, MOG 25.1 was found on the cell surface when
transiently expressed in HeLa cells, where it co-localised
with the cell surface marker CD44 (Fig. 3). Similarly, MOG
25.6 was also expressed at the cell surface (Fig. 3).
MOG 21.0 is predominately expressed in the endoplasmic
reticulum
In contrast to 25.6 and 25.1, the shorter isoforms 21.0, 22.7
and 20.5 clearly demonstrated a more intracellular pattern of
expression (Fig. 3). MOG 21.0 had a reticular pattern of
expression, which co-localised perfectly with the ER marker
calreticulin (Fig. 3). Therefore, MOG 21.0 was mainly
retained in the ER with very little cell surface expression.
This result ﬁts with the slow rates of export of MOG 21.0 as
observed in Fig. 2a.
MOG 22.7 is internalised into the endocytic system
MOG 22.7 was capable of being expressed at the cell surface
showing co-localisation with CD44 (Fig. 3). However, much
of the protein was found in distinct vesicles. To characterise
the type of vesicle more thoroughly we compared the
localisation of MOG 22.7 with a variety of cell markers
including those for the ER (calreticulin), cis-Golgi (GM130),
trans-Golgi (TGN-46), endosomes (Vps26), mitochondria
(ATP synthase), early endosomes (EEA1) and lysosomes
(LAMP2). MOG 22.7 co-localised with markers of the
endocytic pathway including EEA1, Vps26 and LAMP2
(data not shown). As MOG 22.7 showed a similar rate of
export to the Golgi as the two surface expressed isoforms
MOG 25.6 and 25.1, and was expressed at the cell surface,
we suspected that MOG 22.7 had been internalised from the
cell surface into the endocytic vesicles. To visualise this we
incubated MOG transfected cells with 8.18C5 at 37 C for
2 h to detect only surface expressed MOG and to follow its
internalisation over the time period. The cells were then
ﬁxed and permeabilised, and stained with endocytic markers.
Using this method, we clearly detected MOG 22.7 at the cell
surface and observed its internalisation into the endocytic
system, where it co-localised signiﬁcantly with the endocytic
marker Vps26 (Fig. 4a). As a control, we examined the
internalisation of the surface expressed MOG 25.6, ﬁnding
very little of this MOG isoform co-localising with Vps26
(Fig. 4a). Therefore, after export through the Golgi to the
cell surface, MOG 22.7 is internalised into the endocytic
system.
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Fig. 2 Rates of export of myelin oligodendrocyte glycoprotein (MOG)
isoforms. (a) HeLa cells transiently transfected with the various MOG
isoforms were pulse labelled for 10 min and chased for 0–240 min,
followed by immunoprecipitation of MOG with 8.18C5, digestion with
EndoH and electrophoresis on 12% acrylamide gels. Size markers are
shown on right-hand side (top line, 30 kDa; bottom, 20 kDa). (b)
Western blots of cellular lysates and culture supernatants of HeLa
cells transiently expressing the MOG proteins tagged at the C-termi-
nus with GFP. MOG proteins were detected by blotting with rabbit anti-
GFP. 52 kDa marker is shown.
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endocytic system using this experimental procedure
(Fig. 4a). Thus, although this isoform is mainly expressed
in the ER, any MOG 21.0 released to the cell surface was
internalised into endosomes. As the two isoforms internalised
into endosomes both have the 10B tail these results suggest
that an endosomal-targeting motif is present in the 10B tail.
However, such a motif is only functional in the absence of
exon 8, as isoform 25.6 was not signiﬁcantly internalised into
endosomes.
MOG 20.5 is predominately expressed in the endoplasmic
reticulum
The MOG 20.5 was found at low levels at the cell surface
where it co-localised with CD44 (Fig. 3). However, this
isoform was mainly found in large ‘‘donut-shaped’’ struc-
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Fig. 4 Endoplasmic reticulum (ER) and endosomal localisation of
speciﬁc isoforms. (a) MOG 22.7 and MOG 21.0 are internalised into
endosomes. Confocal micrographs of HeLa cells expressing MOG
22.7, 25.6 or 21.0 incubated with 8.18C5 for 2 h at 37 C to allow
internalisation of MOG. Cells were then ﬁxed, permeabilised, and
stained for the endocytic marker Vps26. Staining was detected with
Alexa secondary antibodies. (b) MOG 20.5 and MOG 21.0 are re-
tained in the ER. Confocal micrographs of HeLa cells transiently
expressing MOG 20.5 and 21.0. Cells were ﬁxed, permeabilised and
stained with the MOG-speciﬁc antibody 8.18C5 and the ER marker
calreticulin.
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Fig. 3 Myelin oligodendrocyte glycoprotein (MOG) isoforms are ex-
pressed at different subcellular sites in HeLa cells. Confocal micro-
graphs of HeLa cells transiently expressing MOG 25.6, 25.1, 21.0,
22.7 and 20.5. Cells were ﬁxed, permeabilised and stained with the
MOG-speciﬁc antibody 8.18C5 and markers for the cell surface
(CD44) or the ER (calreticulin). Staining was detected with Alexa
secondary antibodies.
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Initially, we thought that these were vesicles of the endocytic/
lysosomal system. However, staining with markers for these
compartments revealed only little co-localisation. To our
surprise, we found that these ‘‘donut-shaped’’structures were
actually the ER, as shown with co-localisation with the ER
marker calreticulin (Fig. 4b). These results ﬁt with the slow
rates of export of this isoform as observed in Fig. 2.
The ER is typically reticular in structure as shown by
with staining of untransfected cells with calreticulin
(Fig. 4b). The ‘‘donut-shaped’’ structures resemble the large
intracellular structures or intracellular myelin-like ﬁgures
observed with a mutant form of another myelin protein,
peripheral myelin protein-22 (PMP-22) (Dickson et al.
2002). The mutant form of PMP-22 is retained in the ER,
causing sequestration of another ER chaperone calnexin,
and is associated with Charcot-Marie-Tooth-related neuro-
pathies. In MOG 20.5 expressing cells, we ﬁnd that the
distribution of the ER chaperone calreticulin was altered.
These structures may be caused by misfolding of MOG
20.5 and the sequestration of calreticulin. Some of the
MOG 21.0 that we initially found in a reticular pattern in
the ER (Fig. 3) could also be observed in these ‘‘donut-
shaped’’ structures in the ER (Fig. 4b).
Similar subcellular localisations are observed in the
oligodendrocyte cell line MO3.13
To determine if the striking differences in trafﬁcking, that we
observed in HeLa cells, were also found in oligodendrocytes,
wetransfectedthevariousMOGconstructsintoMO3.13cells,
an immature oligodendrocyte cell line that does not endogen-
ously express MOG (McLaurin et al. 1995; Buntinx et al.
2003). These data revealed a very similar pattern of distribu-
tion to that observed in HeLa cells. MOG 25.6 and 25.1 were
expressed on the cell surface in MO3.13 cells (Fig. 5). MOG
21.0 showed a reticular pattern of expression, which was
conﬁrmed to be the ER (Fig. 5). MOG 22.7 was expressed
mainly in distinct dots, while MOG 20.5 was expressed at the
cell surface with large ‘‘donut-shaped’’structures (Fig. 5).
RNA Expression of myelin oligodendrocyte glycoprotein
isoforms
Complex transcription patterns exist for other myelin protein
genes, such as myelin basic protein and proteolipid protein
genes, with isoforms that show tissue speciﬁcity between the
nervous and immune systems (Givogri et al. 2000). These
myelin protein genes clearly have additional functions in a
number of different cell types that are unrelated to myeli-
nation. This led us to perform a wide-ranging screen for
expression of MOG alternative splicing using svPCR in
various human tissues (adrenal gland, liver, bone marrow,
fetal liver, kidney, lung, placenta, prostate, salivary gland,
skeletal muscle, spleen, testis, thymus, thyroid, trachea,
uterus, colon, small intestine and stomach), blood fractions
and in brain tissue (cerebrum – normal appearing white
matter) from individuals with multiple sclerosis and from
controls. We observed the expression of full-length variants
(MOG 25.1/25.6) in CNS tissues including fetal brain
(Fig. 6a). However, MOG expression was not detected in
any of the peripheral tissues examined except for the heart, in
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Fig. 5 Myelin oligodendrocyte glycoprotein (MOG) isoforms exhibit
distinct cellular distribution in MO3.13 oligodendrocyte cells. Confocal
micrographs of MO3.13 oligodendrocyte cells transiently expressing
MOG isoforms. Cells were treated in acetone before staining with
8.18C5 and Alexa secondary antibodies.
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25.6). This expression most likely originates from myeli-
nated nerves (e.g. vagus ﬁbres) within the heart, although
non-myelinating cell types cannot be discounted.
In contrast, expression of the alternative transcripts (MOG
20.5, MOG 20.2, MOG 22.2, MOG 22.7, MOG 16.3 alpha 4
and MOG16.3 beta 4) was limited to adult CNS tissues with
no detectable expression of these transcripts in either fetal
brain, heart or other human tissue screened. All the MOG
variants including full-length (MOG 25.1/25.6, MOG 20.5,
MOG 20.2, MOG 22.2/22.7, MOG 16.3 alpha 4 and MOG
16.3 beta 4) were detectable in brain tissue (normal appearing
white matter) samples from individuals with multiple scler-
osis (Fig. 6b). None of the MOG variants were detected in
the following blood fractions: mononuclear cells (B- & T-
cells and monocytes), resting CD8+ cells (T-suppressor/
cytotoxic), resting CD4+ cells (T-helper/inducer), resting
CD14+ cells (monocytes), resting CD19+ cells, activated
mononuclear cells, activated CD4+ cells, activated CD8+
cells, activated CD19+ cells.
Discussion
Several alternatively spliced mRNA transcripts arise from the
human MOG gene, and most, if not all, of these are capable
of being translated into protein. In this study, we have shown
that variation in the cytoplasmic tail of MOG signiﬁcantly
affects the rate of export and the site of expression of MOG
proteins (see Table 2 for summary of cellular distribution).
Efﬁcient anterograde trafﬁcking of membrane-bound forms
of MOG to the cell surface appears to be dependent on
having a VLGP·V motif, encoded by exon 7 and 8 and
found in MOG 25.6, 25.1 and 22.7. Internalisation of MOG
into the endocytic system appears to be promoted by the 10B
tail, encoding amino acids LFHLEALSG, in the absence of
exon 8, as observed for 21.0 and 22.7. Such intrinsic
alternative splicing machinery may operate to regulate the
surface expression of MOG. In addition we have shown that
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Fig. 6 RNA expression of myelin oligo-
dendrocyte glycoprotein (MOG) isoforms.
Expression of MOG alternative splice vari-
ants, as analysed by svPCR in a) the
Human Multiple Tissue cDNA Panels and b)
brain (cerebrum) tissue of normal controls
and individuals with multiple sclerosis.
None of the MOG variants were detected in
the following tissues (not shown); adrenal
gland, liver, bone marrow, foetal liver, kid-
ney, lung, placenta, prostate, salivary
gland, skeletal muscle, spleen, testis, thy-
mus, thyroid, trachea, uterus, colon, small
intestine and stomach. Results from
corresponding GAPDH rt-PCR are shown
below the MOG results.
Table 2 Summary of MOG isoform localisation
Isoform Cellular localisation Glycosylation
25.6 Surface Endo H resistant
25.1 Surface Endo H resistant
21.0 Mainly ER. Internalised into endosomes Endo H sensitive
22.7 Surface and endosomes Endo H resistant
20.5 Mainly ER. Low surface expression Endo H sensitive
16.3 Secreted
1860 L. H. Boyle et al.
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  2007 The AuthorsMOG 16.3 can be secreted when expressed in HeLa cells. As
this may have important implications for the pathogenesis of
MS, the conﬁrmation of secreted isoforms of MOG in
humans, such as by immunoprecipitation of MOG from
cerebrospinal ﬂuid, is required.
Using svPCR we detected full-length transcripts of MOG
(MOG 25.6 and 25.1) in fetal brain whereas alternative
variants were not found. These results are consistent with
previous observations and with the implication that the role
of full-length isoforms might be speciﬁc to myelin matur-
ation (Ballenthin and Gardinier 1996; Delarasse et al.
2006). Many of the proposed functions of MOG have been
based on its surface localisation on oligodendrocytes.
However, secreted MOG released into the cerebrospinal
ﬂuid could allow alternative interactions at distant sites.
Expression of MOG in the ER and endocytic system also
expands the potential functions and interactions of MOG. In
addition to a role in cellular transport, cytoplasmic tail
residues are important in signalling. Ligation of surface
expressed MOG induces signalling cascades resulting in the
induction of survival signals, changes in cytosketal integrity
or the activation of stress-related pathways (Marta et al.
2005b). However, there is potential for secreted MOG to
mask such MOG-induced responses. In addition, ligation of
MOG with alternative cytoplasmic tails could have pro-
found effects on these events and may trigger alternative
responses. With the recent identiﬁcation of another 11 MOG
transcripts, alternative sites of expression, function and
signalling events of MOG products unquestionably arise
(Delarasse et al. 2006).
MOG is an important antigen in MS pathogenesis,
activating both T and B lymphocyte responses. Although
low levels of MOG have been detected in the mouse and rat
thymus (Delarasse et al. 2003; Pagany et al. 2003), in
agreement with Bruno et al., we did not detect the expression
in the human thymus (Bruno et al. 2002). Lack of expression
of MOG in thymus could affect central tolerance, as
demonstrated for other antigens.
Differential expression of MOG variants may inﬂuence
protection from or susceptibility to disease. B cell responses
to MOG are considered key to the demyelination of
oligodendrocytes (Iglesias et al. 2001). Secreted forms of
MOG could interact with these demyelinating antibodies and
complement, potentially inhibiting their pathogenic effect on
oligodendrocytes. The death of oligodendrocytes, proposed
to be the ﬁrst trigger in relapsing and remitting MS (Barnett
and Prineas 2004), could expose novel MOG epitopes from
the cytoplasmic tail or may reveal alternatively glycosylated
forms of MOG, which could be recognised by pathogenic
antibodies to the protein (Marta et al. 2005a). The observa-
tion of slow export and ER accumulation of speciﬁc isoforms
(such as MOG 20.5) also raises the possibility that the
misfolding of MOG and consequential ER stress could be
important in certain CNS associated diseases.
Our analysis of brain tissue samples from individuals with
MS did not demonstrate any disease-speciﬁc differences in
splice patterns for MOG in normal appearing white matter.
Analysis using adequate sample size and carefully controlled
real-time svPCR or oligonucleotide hybridisation arrays is
now necessary to determine whether potential quantitative
shifts in expression of alternative transcripts exist between
disease and non-disease states, e.g. in MS plaques, or in
different compartments of the CNS.
Notes
Whilst this paper was in preparation Allamargot and
Gardinier reported that alternative MOG transcripts are
translated into protein in human CNS myelin (Allamargot C.
and Gardinier M.V. (2007) Several MOG isoforms are
expressed in CNS tissue due to alternative splicing of
transcripts from the human MOG gene. J. Neurochem. 101,
298–312). Our results are consistent with their ﬁndings.
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